News
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports NDA submission for icotrokinra for PsO treatment, Phase 2b trial for icotrokinra in UC, VERIFY trial data of rusfertide in PV, and financial results for Q2 2025 -
-
-
-
COMMUNIQUÉ DE PRESSE
Plastic Isn't the Problem, It's What We Do With It That Matters - And SMX Just Changed That
SMX introduces the Plastic Cycle Token (PCT) to revolutionize plastic recycling by embedding tamper-proof markers directly into the material, creating a tradeable asset for a circular economy -
COMMUNIQUÉ DE PRESSE
Verbio SE: Positive momentum for biofuels: Regulatory developments in the EU and the US
Verbio SE closely monitors positive regulatory developments for biofuels in the EU and US, emphasizing the importance of a robust regulatory framework for climate-friendly fuels such as ethanol and biomethane -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Basler AG financial figures for the first six months of 2025: Positive business development in a continuing subdued market environment; company raises forecast for 2025
Basler AG reports positive financial results for the first half of 2025, with sales up by 20% and EBITDA over 100%. The company raises its forecast for 2025 amidst a challenging market environment -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Verbio SE: Preliminary EBITDA for the 2024/2025 financial year below forecast; non-cash impairments in the 2024/2025 consolidated financial statements
Verbio SE reports preliminary EBITDA for 2024/2025 financial year below forecast with non-cash impairments in consolidated financial statements -
